Many Progenics Pharmaceuticals Inc.(PGNX) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Company shares were Upgraded by Needham on Feb 6, 2017 to Strong Buy, Raises Price Target to $ 14 from a previous price target of $11 .
Company has reported several Insider transactions to the SEC, on Apr 22, 2016, Paul J Maddon (director) purchased 5,000 shares at 4.90 per share price.On Jun 15, 2015, Robert J Israel (Executive Vice President, Medi) sold 2,000 shares at 6.83 per share price.
Progenics Pharmaceuticals Last issued its quarterly earnings results on Nov 7, 2016. The company reported $0.52 EPS for the quarter, missing the analyst consensus estimate by $ -0.03. Analyst had a consensus of $0.55. The company had revenue of $53.90 million for the quarter, compared to analysts expectations of $53.59 million. The companys revenue was up 3750.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.14 EPS.
Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) has received a short term rating of sell from experts at Zacks with a rank of 4. The stock has been rated an average of 1 by 2 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys.
Progenics Pharmaceuticals Inc. (NASDAQ:PGNX): 2 Analyst have given the stock of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) a near short term price target of $12.5. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $2.12. The higher price target estimate is at $14 while the lower price estimates are fixed at $11.
Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) witnessed a decline in the market cap on Tuesday as its shares dropped 0.1% or 0.01 points. After the session commenced at $9.65, the stock reached the higher end at $9.74 while it hit a low of $9.4. With the volume soaring to 1,981,912 shares, the last trade was called at $9.67. The company has a 52-week high of $10.27. The company has a market cap of $677 million and there are 70,051,441 shares in outstanding. The 52-week low of the share price is $3.8.
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.